Argá Medtech, a Lausanne, Switzerland-based company providing a cardiac ablation system for treating cardiac arrhythmias, raised €54M in Series B funding.
The round was led by existing investors Advent Life Sciences and Earlybird Health, as well as new investor Gilde Healthcare and an undisclosed investor.
The company intends to use the funds to advance the development of its CSE™ Pulsed Field Ablation (PFA) system for treating AF through the execution of an IDE study in the US and a CE Mark study in the EU.
Led by CEO David Neale, Argá Medtech is developing a coherent sine-burst electroporation™ (CSE™), pulsed field ablation (PFA) system to treat patients with cardiac arrhythmias. The company’s catheter design is able to create circular, linear, and focal lesions, coupled with a CSE™ PFA waveform that allows energy titration based on tissue depth to achieve durable lesions.
Commenting on the news, David Neale said: “This financing enables us to advance toward our goal of validating the CSE™ PFA system in Europe and the US as we work to deliver a safe, fast, and effective treatment to millions of people affected by cardiac rhythm disorders and atrial fibrillation. We are proud of our accomplishments to date, including conducting a 48-patient first-in-human study in Europe, which demonstrated the high performance of our platform in treatingatrial fibrillation.”
With the funding, the company will also expand its US offices in San Diego, CA, in anticipation of its US clinical activities.
FinSMEs
03/03/2024